stents

La era del stent provisional para las bifurcaciones parece llegar a su fin

IVUS in Unprotected LMCA Angioplasty: Should We Change the Way We Use It?

Courtesy of Dr. Carlos&nbsp;Fava. Bifurcation lesions account for about 25% of all angioplasties and it is a challenge for which there is no single treatment strategy. Intravascular ultrasound (IVUS) has proven its usefulness, improving outcomes by reducing mortality in unprotected left main coronary artery (LMCA) angioplasty. A new strategy consists in conducting an IVUS after<a href="https://solaci.org/en/2020/07/14/ivus-in-unprotected-lmca-angioplasty-should-we-change-the-way-we-use-it/" title="Read more" >...</a>

Revascularización vs tratamiento médico inicial en pacientes crónicos

EuroPCR 2020 | Revascularization vs. Initial Medical Treatment in Chronic Patients

There is no survival advantage with invasive coronary revascularization over initial medical treatment in patients with chronic coronary artery disease.&nbsp; However, revascularization did reduce the incidence of unstable angina and its symptoms, according to this new meta-analysis published in Circulation and presented virtually at EuroPCR&nbsp;2020. There was no significant difference in spontaneous infarctions overall, but<a href="https://solaci.org/en/2020/07/08/europcr-2020-revascularization-vs-initial-medical-treatment-in-chronic-patients/" title="Read more" >...</a>

oclusiones totales cronicas plataformas bioabsorbibles stents liberadores de droga

Stenting of Lipid-Rich vs Fibrous and calcified Plaques: Different Prognosis?

Coronary PCI with contemporary drug eluting stents (DES) in lipidic-rich plaques were not associated with increased periprocedural events at long term compared against plaques with no significant lipidic composition.&nbsp; This study recently published in J Am Coll Cardiol looked into the association between lipidic rich plaques detected by near-infrared spectroscopy (NIRS) and clinical events in<a href="https://solaci.org/en/2020/06/24/stenting-of-lipid-rich-vs-fibrous-and-calcified-plaques-different-prognosis/" title="Read more" >...</a>

La coronariografía precoz reduce la mortalidad en SCA sin supradesnivel del ST de alto riesgo

Compare-Acute Sub-Study: Natural History of Non-Culprit Lesions in MI

The aim of this study was to determine the prognostic value of fractional flow reserve (FFR) of non-culprit lesions in STEMI patients.&nbsp; We analyzed data of all Compare-Acute patients (Comparison Between FFR Guided Revascularization Versus Conventional Strategy in Acute STEMI Patients With MVD) after PCI, from lesions assessed with FFR and treated medically.&nbsp; The treating<a href="https://solaci.org/en/2020/06/16/compare-acute-sub-study-natural-history-of-non-culprit-lesions-in-mi/" title="Read more" >...</a>

SOLACI-CACI 2021 Preliminary Agenda

Check out the main topics of the upcoming SOLACI-CACI 2021 Congress. Save the Date! &nbsp; Special Session About the COVID-19 Pandemic &nbsp; Managing Cardiovascular disease and Cath Lab during the COVID-19 Pandemic Live Case Transmissions Coronary and Structural cases performed by distinguished international and national operators. Coronary Track &nbsp; Myocardial Infarction, Left Main session, Complex<a href="https://solaci.org/en/2020/06/09/solaci-caci-2021-preliminary-agenda/" title="Read more" >...</a>

TAVI: Balón expandible o autoexpandible ¿Cuál es la respuesta?

TAVR: Balloon-Expandable or Self-Expanding Valves, Which Is the Answer?

Courtesy of Dr. Carlos&nbsp;Fava. Transcatheter aortic valve replacement (TAVR) has shown benefit and is currently moving towards low-risk patients, as well as bicuspid aortic valves and (to a lower extent) aortic regurgitation. However, we must ponder on which valve should be used on each patient: balloon-expandable (BE) or self-expanding (SE) valve? They represent different technologies<a href="https://solaci.org/en/2020/06/03/tavr-balloon-expandable-or-self-expanding-valves-which-is-the-answer/" title="Read more" >...</a>

struts ultrafinos

BIOFLOW V: Ultrathin Struts Confirm their Benefits

For several years we have been testing new devices that have introduce changes with respect to their predecessors in the hope they will bring clinical benefits.&nbsp; And so, the different generations of drug eluting stents came about (DES) even though we found ourselves stuck in the second generation, with the classical everolimus eluting stents. All<a href="https://solaci.org/en/2020/05/07/bioflow-v-ultrathin-struts-confirm-their-benefits/" title="Read more" >...</a>

El uso del ultrasonido intravascular en la angioplastia de tronco no protegido se asocia con mejores resultados en comparación con la angioplastia guiada solo por angiografía.

IVUS in Left Main Coronary Artery Angioplasty: Luxury or Necessity?

Technique advancements in left main coronary artery angioplasty have turned this procedure into a reasonable alternative to surgery, particularly in patients with a low or intermediate Syntax score and, obviously, those in whom surgery was contraindicated. Results can be credited to a refinement in technique, better drug-eluting stents, better patient selection, and frequent use of<a href="https://solaci.org/en/2020/04/15/ivus-in-left-main-coronary-artery-angioplasty-luxury-or-necessity/" title="Read more" >...</a>

Virtual ACC 2020 | PRECOMBAT: 10 Years for Surgery vs. Angioplasty in Left Main Coronary Artery Disease

After 10&nbsp;years of follow-up, there were no significant differences in the rates of major adverse cardiovascular or cerebrovascular events among patients with left main coronary artery disease randomized to angioplasty or surgery. Since this was the first study to randomize patients with left main coronary artery disease to angioplasty or surgery, it enrolled very few<a href="https://solaci.org/en/2020/04/02/virtual-acc-2020-precombat-10-years-for-surgery-vs-angioplasty-in-left-main-coronary-artery-disease/" title="Read more" >...</a>

Virtual ACC 2020 | TWILIGHT-COMPLEX: Ticagrelor Monotherapy in the Most “Dangerous” Angioplasties

The original TWILIGHT findings in more than 9000&nbsp;patients who underwent angioplasty were presented last year at TCT and showed a 3.1% absolute risk reduction in BARC&nbsp;2, 3, or 5 bleeding with no increase in death, infarction, or stroke in patients who received ticagrelor and placebo compared with patients who received ticagrelor and aspirin. All patients<a href="https://solaci.org/en/2020/04/02/virtual-acc-2020-twilight-complex-ticagrelor-monotherapy-in-the-most-dangerous-angioplasties/" title="Read more" >...</a>

Top